Research Topics
Genomes and GenesSpecies | Tineke WoltersSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancerTineke Wolters
Department of Pathology, Erasmus MC, Rotterdam, The Netherlands Department of Urology, Erasmus MC, Rotterdam, The Netherlands
Eur Urol 57:821-9. 2010..In addition, tumour volume might be of value in substaging of pathologic tumour stage (pT2) prostate cancer (PCa)...
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?Tineke Wolters
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
BJU Int 101:283-8. 2008..To identify pathological features in non-malignant sextant prostate needle biopsies and assess their predictive value for detecting prostate cancer on biopsy 4 years later...
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trialTineke Wolters
Department of Pathology, Erasmus MC Rotterdam, The Netherlands
J Urol 185:121-5. 2011..5 ml for the index tumor. In this study we reassess this tumor volume threshold for clinically insignificant prostate cancer using an independent data set...
The effect of study arm on prostate cancer treatment in the large screening trial ERSPCTineke Wolters
Department of Urology, Erasmus MC, Rotterdam, The Netherlands
Int J Cancer 126:2387-93. 2010..Therefore, differences in treatment between arms are unlikely to play a major role in the interpretation of the results of the ERSPC...
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)Tineke Wolters
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 55:385-92. 2009..The value of prostate-specific antigen velocity (PSAV) in screening for prostate cancer (PCa) and especially for clinically significant PCa is unclear...
The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomyTineke Wolters
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
BJU Int 106:280-6. 2010....
False-negative prostate needle biopsies: frequency, histopathologic features, and follow-upTineke Wolters
Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
Am J Surg Pathol 34:35-43. 2010....
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancerMonique J Roobol
Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
Eur Urol 57:79-85. 2010..Screening for prostate cancer (PC) is controversial due to uncertainties about its efficiency...
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancerClaartje Gosselaar
Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
BJU Int 101:685-90. 2008..To determine the value of a hypoechoic lesion (HL)-directed biopsy in addition to a systematic sextant biopsy for detecting prostate cancer...
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparisonRoderick C N van den Bergh
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
BJU Int 102:1068-73. 2008....
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100)Monique J Roobol
Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
Eur Urol 58:893-9. 2010..Therefore a high PCA3 score should result in a high positive predictive value (PPV) and specificity for a positive biopsy...
Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?Roderick C N van den Bergh
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer 116:1281-90. 2010..Delay before radical treatment caused by active surveillance may be associated with an impaired chance of curability...
Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortalityPim J van Leeuwen
Erasmus University Medical Center, Rotterdam, The Netherlands
Can J Urol 18:6018-24. 2011..Value of characteristics assessed prior to diagnosis predicting aggressive prostate cancer, metastases and mortality in men participating in a screening study were identified...
Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomyTineke Wolters
Department of Urology, Erasmus MC Rotterdam, The Netherlands
Prostate 72:108-15. 2012..Objective of this study is to compare PC detected by PSA screening at subsequent screening rounds and treated by radical prostatectomy (RP) with PC incidentally found in cystoprostatectomy specimens...
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a reviewRoderick C N van den Bergh
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 54:505-16. 2008..The kinetics of prostate specific antigen (PSA) are generally assumed to be indicative of tumour progression and are therefore used in clinical decision-making in men on active surveillance for early prostate cancer...
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kineticsFritz H Schroder
Department of Urology, Erasmus MC, Rotterdam, The Netherlands
Eur Urol 53:468-77. 2008..Screening for PCa has not yet been shown to lower PCa mortality. Still, opportunistic screening is wide spread in Europe and in most other parts of the world...
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcomeStijn Roemeling
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 51:1244-50; discussion 1251. 2007..To study active surveillance as a management option for the important number of prostate cancer patients who would not have been diagnosed in the absence of screening...
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsiesFritz H Schroder
Department of Urology, Erasmus MC, University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Eur Urol 57:256-66. 2010..The appropriate way of biopsying a prostate remains controversial. Is sextant biopsy still adequate with repeat screening?..
Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcomeAgnes Marije Hoogland
Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
BJU Int 108:1356-62. 2011..To evaluate their potential clinical implementation in a preoperative setting...
Anxiety and distress during active surveillance for early prostate cancerRoderick C N van den Bergh
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer 115:3868-78. 2009..In this study, these feelings were quantified, and their associations with various psychologic, medical, demographic, and decision-related factors were assessed...
Screening: should more biopsies be taken in larger prostates?Pim Van Leeuwen
Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands
BJU Int 104:919-24. 2009..To assess the number of missed prostate cancers and the frequency of aggressive disease when taking lateralized sextant prostate biopsies, irrespective of the total prostate volume (Pvol), during screening for prostate cancer...
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic testMonique J Roobol
Erasmus MC, University Medical Centre, Department of Urology, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Eur Urol 58:475-81. 2010..The performance characteristics of serum prostate-specific antigen (PSA) as a diagnostic test for prostate cancer (PCa) are poor. The performance of the PCa antigen 3 (PCA3) gene as a primary diagnostic is unknown...
Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), RotterdamClaartje Gosselaar
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 55:139-46. 2009..Evidence indicates that an abnormal digital rectal examination (DRE) is a risk factor for high-grade prostate cancer (PC)...
Non-prostatic pathology on prostate needle-biopsy - colorectal carcinoid: a case reportRoderick Cn van den Bergh
Department of Urology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
Cases J 2:75. 2009..abstract:..
